tbuckley/cabot-search huggingface dataset:
Application of the subsequent injury categorisation model for longitudinal injury surveillance in elite rugby and cricket: intersport comparisons and inter-rater reliability of coding
Authors: Isabel S Moore, Stephen Mount, Prabhat Mathema, Craig Ranson
Journal: British Journal of Sports Medicine (2017)

When an athlete has more than one injury over a time period, it is important to determine if these are related to each other or not. The subsequent injury categorisation (SIC) model is a method designed to consider the relationship between an index injury and subsequent injury(ies).The primary aim was to apply SIC to longitudinal injury data from two team sports: rugby union and cricket. The secondary aim was to determine SIC inter-rater reliability.Rugby union (time-loss; TL) and cricket (TL and non-time-loss; NTL) injuries sustained between 2011 and 2014 within one international team, respectively, were recorded using international consensus methods. SIC was applied by multiple raters, team clinicians, non-team clinicians, and a sports scientist. Weighted kappa and Cohen's kappa scores were calculated for inter-rater reliability of the rugby union TL injuries and cricket NTL and TL injuries.67% and 51% of the subsequent injuries in rugby union and cricket respectively were categorised as injuries to a different body part not related to an index injury (SIC code 10). At least moderate agreement (weighted and Cohen kappa ≥0.60) was observed for team clinicians and the non-team clinician for both sports. Including NTL and TL injuries increased agreement between team clinician and non-team clinician, but not between clinician and sports scientist.The most common subsequent injury in both sports was an injury to a different body part that was not related to an index injury. The SIC model was generally reliable, with the highest agreement between clinicians working within the same team. Recommendations for future use of SIC are provided based on the proximity of the rater to the team and the raters' level of clinical knowledge.
Bleeding Events and Safety Outcomes in Patients with Hemophilia a with Inhibitors: A Prospective, Multicenter, Non-Interventional Study
Authors: Johnny Mahlangu, Johannes Oldenburg, Michael U Callaghan, Midori Shima, Elena Santagostino, Michaela Lehle, Marianne Uguen, Ceri Hirst, Maggie Moore, Michael Recht, Claudia Garcia, Renchi Yang, Rebecca Kruse-Jarres
Journal: Blood (2016)
Abstract PD8-03: Differences in the mutational landscape in African Americans and Caucasians with triple negative breast cancer
Authors: FO Ademuyiwa, Y Tao, J Luo
Journal: Cancer Research (2017)

Abstract Background-Triple negative breast cancer (TNBC) occurs at a higher frequency in African American (AA) premenopausal women compared with Caucasians. It is unclear if the biology and clinical outcome of TNBC is different in AA versus Caucasians. In this study, we sought to evaluate differences in the molecular pathology of TNBC in a large cohort of AA and Caucasians. Methods-Using publicly available data from The Cancer Genome Atlas, we identified all patients with TNBC who had information on race. We analyzed the differences in clinical characteristics and tumor somatic mutations by race from whole exome sequencing using student's t test or one-way ANOVA for continuous variables and chi square or Fisher's test for categorical variables. Exome sequencing was performed with coverage of ≥70% and at a depth of 20x. Results-A total of 1104 primary breast cancer patients were identified, of which 178 (16%) had TNBC. Overall, TNBC was more frequent in AA than in Caucasians (33.3% versus 14.9%; p value &amp;lt;0.001). More AA than Caucasians were classified as basal-like from PAM50 gene expression analysis (34.8% versus 16.1%; p value 0.001). No differences in the TNBC cohort were observed, 91% of AA were basal-like versus 81% of Caucasians (p value 0.842). Median tumor somatic mutation counts were higher in AA (39.5) versus Caucasians (34) (p value 0.022). However, no racial differences in the mutation counts in TNBC were observed (AA=56, Caucasians=60, p value 0.399). Somatic mutation analysis revealed racial differences in specific high prevalence (&amp;gt;5%) genes in all patients- [TP53 alterations: 46% in AA versus 27% in Caucasians; p value &amp;lt;0.001, PIK3CA alterations: 23% in AA versus 34% in Caucasians; p value 0.019, and MLL3 alterations: 12% in AA versus 6% in Caucasians; p value 0.028]. The TNBC patients did not have any specific high prevalence (&amp;gt;5%) genes associated with racial differences. AA with breast cancer had a shorter time to progression (TTP) (hazard ratio 1.62, p value 0.014) and worse disease free survival (DFS) than Caucasians. However, racial difference in TTP or DFS were not observed in the TNBC patients. Conclusion-The mutational landscape of breast cancer may be different between AA and Caucasians, but appears to be similar in both races in the cohort with TNBC. Our findings have 2 implications: racial disparities in breast cancer may largely be due to differences in those with hormone receptor positive disease, and secondly, the higher frequency of TNBC in AA is unlikely due to differences in molecular features, but other modifiable factors. Citation Format: Ademuyiwa FO, Tao Y, Luo J. Differences in the mutational landscape in African Americans and Caucasians with triple negative breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr PD8-03.
Outcome with Hyper-CVAD/MTX-Ara-C, a Dose-Intensive Regimen, in Acute Lymphocytic Leukemia and Highly Aggressive Lymphoma: A Preliminary Study in a Single Center in China.
Authors: Ting Niu, Ting Liu, Bing Xiang, Hong Chang, Yong-qian Jia, Huan-ling Zhu
Journal: Blood (2006)
Abstract P2-05-38: Spectral CT based radiomics signature: A potential biomarker for preoperative prediction of lymph node metastasis in breast cancer
Authors: D Dong, X Zhang, M Fang, J Shen, J Tian
Journal: Cancer Research (2017)

Abstract Purpose: To investigate the usefulness of radiomics signature based on computed tomographic (CT) spectral imaging, during the late arterial phase (AP) and portal venous phase (PVP), in preoperative predicting the lymph node (LN) metastasis in breast cancer (BC). patients and methods: This retrospective study was institutional review board approved, and written informed consent was obtained from all patients. We examined 60 female patients (LN metastasis positivity was 50%) with CT spectral imaging during the AP and the PVP and data was gathered from 2014 to 2016. Excised lymph nodes were located and labeled during surgery according to location on preoperative CT images and were evaluated histopathologically. For each patient, two 3D Hounsfeld Unit (HU) gradient maps which revealed the HU change of each voxel were built by quadratic fitting the spectral HU curves during the two phases respectively. Then the radiomics features were then extracted from the regions of BC and a suspicious LN judged manually in these maps. The potential association of the four groups of radiomics features with LN status was assessed by using a Mann-Whitney U test. The area under curves (AUC) of the receiver operating characteristic curves (ROC) were compared with data obtained from the conventional CT image. results: The 3D HU gradient map showed a great power of distinguishing among different components and was considered as a more effective tool for revealing the intratumour heterogeneity than the conventional CT image since the slope of spectral HU curves were significantly higher in malignant tumor. More than 500 radiomics features extracted from the regions of LN during the AP and the PVP exhibited significant differences (P &amp;lt;0.05). Moreover, the numbers of this kind of features extracted from the regions of BC were more than 200. The highest AUC of single feature was 0.70, which was higher than those from the conventional CT image. Conclusion: Quantitative radiomics features based on 3D HU gradient maps have the potential to be exploited as an effective biomarker for preoperative prediction of lymph node metastasis in breast cancer. Citation Format: Dong D, Zhang X, Fang M, Shen J, Tian J. Spectral CT based radiomics signature: A potential biomarker for preoperative prediction of lymph node metastasis in breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-05-38.
Murine recombinant angiotensin-converting enzyme 2 attenuates kidney injury in experimental Alport syndrome
Authors: Eun Hui Bae, Fei Fang, Vanessa R. Williams, Ana Konvalinka, Xiaohua Zhou, Vaibhav B. Patel, Xuewen Song, Rohan John, Gavin Y. Oudit, York Pei, James W. Scholey
Journal: Kidney International (2017)
Comprehensive Genomic Profiling (CGP) of Angioimmunoblastic T-Cell Lymphoma (AITL) to Prospectively Inform Diagnosis and Clinical Management
Authors: Samantha Morley, Jie He, Andrew M. Intlekofer, Mark Bailey, Michelle Nahas, Doron Lipson, Roman Yelensky, Jeffrey Ross, Siraj Ali, Rachel Erlich, Phil Stephens, Vincent A. Miller, Jo-Anne Vergilio, Tariq I Mughal
Journal: Blood (2015)
PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment
Authors: R E Piddock, N Loughran, C R Marlein, S D Robinson, D R Edwards, S Yu, G E Pillinger, Z Zhou, L Zaitseva, M J Auger, S A Rushworth, K M Bowles
Journal: Blood Cancer Journal (2017)

Phosphoinositide-3-kinase and protein kinase B (PI3K-AKT) is upregulated in multiple myeloma (MM). Using a combination of short hairpin RNA (shRNA) lentivirus-mediated knockdown and pharmacologic isoform-specific inhibition we investigated the role of the PI3K p110γ (PI3Kγ) subunit in regulating MM proliferation and bone marrow microenvironment-induced MM interactions. We compared this with inhibition of the PI3K p110δ (PI3kδ) subunit and with combined PI3kδ/γ dual inhibition. We found that MM cell adhesion and migration were PI3Kγ-specific functions, with PI3kδ inhibition having no effect in MM adhesion or migration assays. At concentration of the dual PI3Kδ/γ inhibitor duvelisib, which can be achieved in vivo we saw a decrease in AKT phosphorylation at s473 after tumour activation by bone marrow stromal cells (BMSC) and interleukin-6. Moreover, after drug treatment of BMSC/tumour co-culture activation assays only dual PI3kδ/γ inhibition was able to induce MM apoptosis. shRNA lentiviral-mediated targeting of either PI3Kδ or PI3Kγ alone, or both in combination, increased survival of NSG mice xeno-transplanted with MM cells. Moreover, treatment with duvelisib reduced MM tumour burden in vivo. We report that PI3Kδ and PI3Kγ isoforms have distinct functions in MM and that combined PI3kδ/γ isoform inhibition has anti-MM activity. Here we provide a scientific rationale for trials of dual PI3kδ/γ inhibition in patients with MM.
Abstract 89: MitoTimer Mouse: a Novel Tool for the Study of Mitochondrial Turnover in vivo
Authors: Aleksandr B Stotland, Jennifer Ramil, Roberta A Gottlieb
Journal: Circulation Research (2015)

In order to study mitochondrial turnover at the level of a single mitochondrion, our laboratory has developed the MitoTimer protein. Timer is a mutant of DsRed fluorescent protein developed by Terskikh et al. The Timer protein transitions from green fluorescence to a more stable red conformation as it matures over a span of 48 h. Furthermore, the protein is very stable under physiological conditions, insensitive to variations in ionic strength, and changes in pH between 7.0 and 8.0. Notably, Timer maturation from green to red is significantly slowed in deoxygenated buffer, suggesting that molecular oxygen plays a part in fluorophore maturation. We fused the Timer protein with the mitochondrial signal sequence from the cytochrome c oxidase subunit VIII (COX8) to target the protein to the inner membrane of the mitochondria, and further cloned the protein into a construct with a cardiac-restricted α-myosin heavy chain promoter. This construct was used to create the α-MHC MitoTimer mice. Surprisingly, initial analysis of the hearts from these mice reveals a remarkable degree of heterogeneity in the ratio of red-to- green fluorescence of MitoTimer in cardiac tissue. Furthermore, individual mitochondria within cardiomyocytes display a higher red-to-green fluorescence, implying a block in import of newly synthesized MitoTimer that would be caused by the lack of a high membrane potential, indicative of older, dysfunctional mitochondria. Initial studies suggest that these mice represent an elegant tool for the investigation of mitochondrial turnover in the heart.
COMPARATIVE STUDIES OF PATIENTS WITH TAKAYASU ARTERITIS IN JAPAN, KOREA AND INDIA : Comparison of Clinical Manifestations, Angiography and HLA-B Antigen
Authors: Michiyoshi Yajima, Fujio Numano, Young B. Park, S. Sagar
Journal: Circulation (1993)

Comparative study of Takayasu arteritis in 3 Asian countries (India, Korea and Japan) has revealed some significant differences. In angiographic findings, Japanese patients more frequently have lesions at the aortic arch and/or its branches (99% of 96 cases), while most lesions in Korean (76% of 109 cases) and Indian patients (92% of 50 cases) are at the abdominal aorta. The presence of HLA-Bw52 or B5 is closely associated with Takayasu arteritis in all 3 Asian countries. The complications in 108 Japanese, 101 Korean and 50 Indian patients were also compared. The most frequent complications were aortic regurgitation in Japan and hypertension in the other 2 countries. Death occurred most frequently due to congestive heart failure or sudden death resulting from aortic regurgitation in Japan, but resulting from hypertension in Korea and India.
The Effect of Proteasome Subunit Beta Type 1 P11A Polymorphism on the Survival of Multiple Myeloma Patients Treated with First Line Bortezomib Based Chemotherapy
Authors: Gergely Varga, Gabor Mikala, Gergely Szombath, Katalin Balassa, Katalin Piroska Kiss, Attila Tordai, Hajnalka Andrikovics, Tamas Masszi
Journal: Blood (2015)
Deregulated Expression of HDAC9 in B-Cells Leads to Lymphoproliferative Disorders As Well As Germinal Center and Post-Germinal Center Derived Lymphomas
Authors: Veronica Sylvina Gil, Sven Stengel, Govind Bhagat, Louise Howell, Daniel Catovsky, Laura Pasqualucci, Kevin Petrie, Arthur Zelent
Journal: Blood (2012)
Association Between Incomplete Neoadjuvant Radiotherapy and Survival for Patients With Locally Advanced Rectal Cancer
Authors: Kyle Freischlag, Zhifei Sun, Mohamed A. Adam, Jina Kim, Manisha Palta, Brian G. Czito, John Migaly, Christopher R. Mantyh
Journal: JAMA Surgery (2017)

Failing to complete chemotherapy adversely affects survival in patients with colorectal cancer. However, the effect of incomplete delivery of neoadjuvant radiotherapy is unclear.To determine whether incomplete radiotherapy delivery is associated with worse clinical outcomes and survival.Data on 17 600 patients with stage II to III rectal adenocarcinoma from the 2006-2012 National Cancer Database who received neoadjuvant chemoradiotherapy followed by surgical resection were included. Multivariable regression methods were used to compare resection margin positivity, permanent colostomy rate, 30-day readmission, 90-day mortality, and overall survival between patients who received complete (45.0-50.4 Gy) and incomplete (<45.0 Gy) doses of radiation as preoperative therapy.The primary outcome measure was overall survival; short-term perioperative and oncologic outcomes encompassing margin positivity, permanent ostomy rate, postoperative readmission, and postoperative mortality were also assessed.Among 17 600 patients included, 10 862 were men, with an overall median age of 59 years (range, 51-68 years). Of these, 874 patients (5.0%) received incomplete doses of neoadjuvant radiation. The median radiation dose received among those who did not achieve complete dosing was 34.2 Gy (interquartile range, 19.8-40.0 Gy). Female sex (adjusted odds ratio [OR] 0.69; 95% CI, 0.59-0.81; P < .001) and receiving radiotherapy at a different hospital than the one where surgery was performed (OR, 0.72; 95% CI, 0.62-0.85; P < .001) were independent predictors of failing to achieve complete dosing; private insurance status was predictive of completing radiotherapy (OR, 1.60; 95% CI, 1.16-2.21; P = .004). At 5-year follow-up, overall survival was improved among patients who received a complete course of radiotherapy (3086 [estimated survival probability, 73.2%] vs 133 [63.0%]; P < .001). After adjustment for demographic, clinical, and tumor characteristics, patients receiving a complete vs incomplete radiation dose had a similar resection margin positivity (OR, 0.99; 95% CI, 0.72-1.35; P = .92), permanent colostomy rate (OR, 0.96; 95% CI, 0.70-1.32; P = .81), 30-day readmission rate (OR, 0.92; 95% CI, 0.67-1.27; P = .62), and 90-day mortality (OR, 0.72; 95% CI, 0.33-1.54; P = .41). However, a complete radiation dose had a significantly lower risk of long-term mortality (adjusted hazard ratio, 0.70; 95% CI, 0.59-0.84; P < .001).Achieving a target radiation dose of 45.0 to 50.4 Gy is associated with a survival benefit in patients with locally advanced rectal cancer. Aligning all aspects of multimodal oncology care may increase the probability of completing neoadjuvant therapy.
Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma
Authors: Alfred L. Garfall, Edward A Stadtmauer, Marcela V. Maus, Wei-Ting Hwang, Dan T. Vogl, Adam D. Cohen, Brendan M Weiss, David L Porter, Noelle Frey, Michael Milone, Patricia Mangan, Maria Krevvata, Emily Ayers, Karen Dengel, Naseem DS Kerr, Simon F. Lacey, Jan Joseph Melenhorst, David E Ambrose, Fang Chen, Vanessa E Gonzalez, Irina Kulikovskaya, Minnal Gupta, Jeffrey Finklestein, Anne Lamontagne, Matthew O'Rourke, Megan Suhoski Davis, Alexander Malykhin, Bruce L Levine, Carl H June
Journal: Blood (2016)
Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line
Authors: Michele Baccarani, Fausto Castagnetti, Bengt Simonsson, Kimmo Porkka, Ibrahim C. Haznedaroglu, Arnon Nagler, Francesca Palandri, Giovanna Rege Cambrin, Luciano Levato, Fausto Palmieri, Elisabetta Abruzzese, Ugur Özbek, Veli Kairisto, Hans Bostrom, Johann Lanng Nielsen, Henrik Hjorth-Hansen, Ole Weis-Bjerrum, Nicoletta Testoni, Giovanni Martinelli, Fabrizio Pane, Giuseppe Saglio, Gianantonio Rosti
Journal: Blood (2008)
Long-Term Outcomes of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Etoposide and Cyclophosphamide
Authors: Amir Siddiqui, Donna E. Hogge, Thomas J. Nevill, Stephen H. Nantel, Michael J Barnett, Raewyn Broady, Donna L. Forrest, Sujaatha Narayanan, Maryse M Power, Kevin W. Song, Cynthia L. Toze, Yasser Abou Mourad, Heather J. Sutherland, Alina S. Gerrie, David Sanford
Journal: Blood (2016)
Contents Vol. 84, 2015
Authors: Michael Berk, Julie A. Pasco, Lana J. Williams, Sharon L. Brennan-Olsen, Felice N. Jacka, Steffi Weidt, Richard Klaghofer, Alexa Kuenburg, Annette Beatrix Bruehl, Aba Delsignore, Steffen Moritz, Michael Rufer, Luigi Grassi, Federica Ruffilli, Maria Alejandra Berardi, Rosangela Caruso, Elena Meggiolaro, Elisabeth Andritsch, Agustina Sirgo, Eva Juan Linares, Marta Bellé, Sara Massarenti, Maria Giulia Nanni, Richard Balon, Wolfgang Herzog, Katrin E. Giel, Elisabeth J. Leehr, Sandra Becker, Florian Junne, Ulrike Schmidt, Stephan Zipfel, Aaron T. Beck, Paulo Knapp, Christian Kieling, Jose de Leon, Enrique Baca-García, Hilario Blasco-Fontecilla, Filip Smit, Pim Cuijpers, Claudia Buntrock, David Ebert, Dirk Lehr, Heleen Riper, Matthias Berking, Mario Altamura, Piero Porcelli, Angela Balzotti, Claudio R.M. Massaro, Antonello Bellomo, Jan F. Wiborg, Jose van Bussel, Agaat van Dijk, Gijs Bleijenberg, Hans Knoop, Vladan Starcevic, Vlasios Brakoulias, Kirupamani Viswasam, David Berle, Satz Mengensatzproduktion, Druckerei Stückle, Druckerei Stückle, IOR-IRST Psycho-Oncology and UniFE Psychiatry Co-Authors
Journal: Psychotherapy and Psychosomatics (2015)
Innate immunity to RNA virus is regulated by temporal and reversible sumoylation of RIG-I and MDA5
Authors: Ming-Ming Hu, Chen-Yang Liao, Qing Yang, Xue-Qin Xie, Hong-Bing Shu
Journal: The Journal of Experimental Medicine (2017)

Sensing of viral RNA by the cytosolic receptors RIG-I and melanoma differentiation-associated gene 5 (MDA5) leads to innate antiviral response. How RIG-I and MDA5 are dynamically regulated in innate antiviral response is not well understood. Here, we show that TRIM38 positively regulates MDA5- and RIG-I–mediated induction of downstream genes and acts as a SUMO E3 ligase for their dynamic sumoylation at K43/K865 and K96/K888, respectively, before and after viral infection. The sumoylation of MDA5 and RIG-I suppresses their K48-linked polyubiquitination and degradation in uninfected or early-infected cells. Sumoylation of the caspase recruitment domains of MDA5 and RIG-I is also required for their dephosphorylation by PP1 and activation upon viral infection. At the late phase of viral infection, both MDA5 and RIG-I are desumoylated by SENP2, resulting in their K48-linked polyubiquitination and degradation. These findings suggest that dynamic sumoylation and desumoylation of MDA5 and RIG-I modulate efficient innate immunity to RNA virus and its timely termination.
Phase 2 Study of Talabostat and Rituximab in Patients with Advanced Chronic Lymphoctyic Leukemia (CLL) Previously Treated with a Rituximab/Fludarabine Regimen.
Authors: Khuda D. Khan, Susan O’Brien, Kanti R. Rai, Jennifer R. Brown, Perry Cook, Anne Marie Maddox, Alison M. Duarte, Eric J. Haltom, Margaret J. Uprichard
Journal: Blood (2005)
Modified-CHOP with Reduced Dose of Non-Pegylated Liposomal Doxorubicin ± Rituximab in First Line Treatment for Elderly Patients with Aggressive Lymphoma Non Suitables for Standard Chemotherapy.
Authors: Eva Gimeno, Blanca Sánchez, Alberto Alvarez, Carme Pedro, Eugenia Abella, Miquel Gomez, Silvia Saumell, Josep Comin, Carles Besses, Antonio Salar
Journal: Blood (2009)